TESTIM Drug Patent Profile

When do Testim patents expire, and what generic alternatives are available?

Testim is a drug marketed by Endo Operations and is included in one NDA.

The generic ingredient in TESTIM is testosterone. There are sixty-nine drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the testosterone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Testim

A generic version of TESTIM was approved as testosterone by ACTAVIS LABS UT INC on January 27^th, 2006.

Summary for TESTIM

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	63
Clinical Trials:	16
Patent Applications:	4,602
Drug Prices:	Drug price information for TESTIM
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TESTIM
What excipients (inactive ingredients) are in TESTIM?	TESTIM excipients list
DailyMed Link:	TESTIM at DailyMed

See drug prices for TESTIM

See drug sales revenues for TESTIM

Recent Clinical Trials for TESTIM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Endo Pharmaceuticals	Phase 4
Instituto de Investigacion Sanitaria La Fe	Phase 3
Marianne Andersen	Phase 4

See all TESTIM clinical trials

Pharmacology for TESTIM

Drug Class	Androgen
Mechanism of Action	Androgen Receptor Agonists

Paragraph IV (Patent) Challenges for TESTIM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TESTIM	Gel	testosterone	1%	021454	1	2008-08-21

US Patents and Regulatory Information for TESTIM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Endo Operations	TESTIM	testosterone	GEL;TRANSDERMAL	021454-001	Oct 31, 2002	AB2	RX	Yes	Yes

Expired US Patents for TESTIM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Endo Operations	TESTIM	testosterone	GEL;TRANSDERMAL	021454-001	Oct 31, 2002
Endo Operations	TESTIM	testosterone	GEL;TRANSDERMAL	021454-001	Oct 31, 2002
Endo Operations	TESTIM	testosterone	GEL;TRANSDERMAL	021454-001	Oct 31, 2002
Endo Operations	TESTIM	testosterone	GEL;TRANSDERMAL	021454-001	Oct 31, 2002
Endo Operations	TESTIM	testosterone	GEL;TRANSDERMAL	021454-001	Oct 31, 2002

EU/EMA Drug Approvals for TESTIM

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Warner Chilcott UK Ltd.	Intrinsa	testosterone	EMEA/H/C/000634Intrinsa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.	Withdrawn	no	no	no	2006-07-28
Warner Chilcott  Deutschland GmbH	Livensa	testosterone	EMEA/H/C/000630Livensa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.	Withdrawn	no	no	no	2006-07-28

International Patents for TESTIM

See the table below for patents covering TESTIM around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	6738487
Canada	1312281	ADMINISTRATION TRANSDERMIQUE DE MEDICAMENTS (TRANSDERMAL DELIVERY OF DRUGS)
Switzerland	666813	ARZNEIMITTEL ZUR TRANSDERMALEN VERABREICHUNG.
Germany	3690626
Denmark	167343

Supplementary Protection Certificates for TESTIM

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
8703473	91289	Luxembourg		PRODUCT NAME: TESTIM; REGISRATION NO 1768/92

TESTIM (testosterone gel) market dynamics and financial trajectory: exclusivity, generic/biosimilar risk, and revenue outlook

Last updated: July 29, 2026

TESTIM is a testosterone replacement therapy (TRT) gel product with a long commercial history and shrinking IP defensibility due to patent aging and formulation/method-of-use estate consolidation risk. Market dynamics are dominated by (1) payer and formulary preference for lower-cost testosterone options (including generics and AB-rated equivalents), (2) safety and utilization scrutiny tied to testosterone prescribing trends and label enforcement, and (3) supply and manufacturing continuity for gel pumps and tubes. Financial trajectory has tracked U.S. testosterone gel demand plus competitive price pressure from AB-rated products after exclusivity, with incremental growth constrained by market maturity and frequent “switch” behavior across manufacturers.

What patents protect TESTIM and what’s the practical impact on market share?

How strong is TESTIM’s patent estate vs. other testosterone gels?

TESTIM’s IP protection historically concentrated on composition/formulation and delivery characteristics (gel-based topical testosterone) plus potential method-of-use claims tied to dosing regimens. In practical terms, the market share impact is driven less by headline patent counts and more by whether key patents remain enforceable through U.S. generic entry windows (Orange Book status) and whether litigation settlements prevent launch for specific challengers.

Market impact channels

• Exclusivity-to-entry channel: As primary patents and exclusivity periods expire, AB-rated gel products gain shelf access, accelerating unit and revenue erosion for the originator.
• Litigation-to-settlement channel: Narrow settlements tied to specific generic applicants can create staggered entry dates and intermittent volume retention.
• Formulation-to-generic-design channel: Even after brand exclusivity fades, some “next-launch” products may design around by changing permeation/excipient profiles, which affects bioavailability equivalence and payer acceptance.

Which jurisdictions matter most for exclusivity and generic entry?

For U.S. launch and revenue risk, the key is whether Orange Book-listed patents block or delay Paragraph IV litigation and approval/launch of AB-rated products. For global revenue, the equivalent constraints are country-specific patent term and exclusivity regimes in major markets where testosterone gel sales exist, but the revenue sensitivity is usually highest in the U.S. due to pricing, reimbursement leverage, and generic penetration speed.

When does TESTIM lose exclusivity and what generic entry risks exist for TESTIM?

How do exclusivity and patent expiration translate into revenue erosion?

For mature testosterone gels, generic entry risk typically manifests as:

• Pre-expiration “aging”: Revenue flattens as prescribers begin switching to lower-cost alternatives on formulary.
• Launch event “step-down”: Once AB-rated products reach market, wholesale acquisition cost (WAC) and net price compress, and brand unit share declines quickly.
• Post-launch consolidation: After 12 to 24 months, remaining share depends on differentiated packaging, contracting, and rebate intensity rather than clinical switching.

What is the typical timeline pattern for testosterone gels?

Across TRT gels, the pattern often follows:

1. core patents approaching expiration,
2. Paragraph IV challenges (if any) timed around filing and FDA approval,
3. settlement-triggered delayed launches for specific applicants,
4. rapid generalization once multiple AB options exist.

TESTIM’s trajectory fits that maturity framework: competition intensifies once multiple AB products become interchangeable, and brand profitability becomes highly dependent on rebate strategy and inventory channel management.

What is the Orange Book status of TESTIM and which patents are most likely to matter for challengers?

How to interpret Orange Book listings for market forecasting

Orange Book listings drive litigation leverage and the generic launch schedule:

• Composition/formulation patents affect whether generic sponsors can proceed with an approved ANDA for an equivalent product.
• Method-of-use patents can be carved around if the ANDA does not seek labeling coverage, depending on claim scope.
• Manufacturing process patents can delay design-around if claims are broadly drafted and difficult to reproduce without infringing.

Forecast logic for financial trajectory

• If Orange Book coverage thins to fewer, narrower patents, launch timing becomes more predictable and contract dynamics shift toward cost minimization.
• If remaining patents include broad formulation or delivery claims, the brand can extract longer exclusivity via litigation or settlement.

Which companies compete with TESTIM and how do pricing and formulary dynamics shape revenue?

Competitive landscape: testosterone gel shelf contest

TESTIM competes in a crowded TRT topical gel category where payers steer toward:

• lower-cost generics and AB equivalents,
• step-therapy criteria,
• preferred pharmacy networks and rebate contracts.

Key market dynamics

• Net price pressure dominates: In mature gel markets, originator revenue declines faster than unit volumes because net pricing falls via rebates and contracting.
• Switching is payer-driven: Prescribers often follow formulary status and patient-specific access rules (coverage denials, prior authorizations).
• Product form factors matter for adherence: Pumps vs. tubes can influence patient experience, but the category remains interchangeable for many insurers once AB-rated.

How does channel strategy affect TESTIM financial performance?

For brands in crowded steroidal and hormonal replacement categories, revenue tracks:

• distribution agreements and buy-in terms,
• inventory management that avoids channel stuffing penalties,
• rebate and patient assistance program design.

As generics enter, brands often maintain supply to preserve prescriber inertia, but revenue depends on how quickly rebates ramp and whether contracts lock in a premium.

What formulations are protected by TESTIM and how does formulation protection affect generic design-around?

Gel dosing, excipients, and permeation: why formulation patents can still matter

Even when the active ingredient is off-patent, formulation patents can protect:

• the gel matrix,
• spreadability and drying characteristics,
• excipient systems that influence absorption,
• dosing uniformity across pump/tube use.

Design-around levers for generics Generic sponsors can pursue:

• alternative excipient blends,
• changed concentrations and/or viscosity targets,
• modified packaging that preserves dose delivery while attempting non-infringement.

If these changes achieve “equivalence” and pass FDA bioequivalence assessments, payer acceptance follows quickly, compressing brand share.

What patent litigation affects TESTIM and how do settlements alter launch timing?

Litigation-driven launch sequencing

Patent litigation in the testosterone gel category typically produces:

• delayed launches for specific Paragraph IV challengers via settlement,
• partial carve-outs where only some labels are blocked,
• faster entry once a court narrows or invalidates coverage.

Financial consequence A settlement that limits launch for one applicant can preserve revenue temporarily, but the market usually converges once multiple AB products exist, and brand revenue then follows category-wide pricing compression.

What is the FDA regulatory status of TESTIM and how does it affect market access?

FDA pathway implications for generic competition

TESTIM is an approved NDA product. Generics compete through ANDAs seeking AB-rated status. Once ANDAs are approved, substitution depends on:

• state substitution rules,
• pharmacy benefit manager (PBM) formularies,
• therapeutic interchange policies.

Why FDA status matters for revenue forecasting When FDA approvals expand the set of interchangeable gels, payer contracting typically re-rates the category quickly, accelerating net revenue decline for the originator.

How does TESTIM compare with other testosterone gels and what drives relative performance?

Brand vs. AB-rated competitors: what typically explains relative outperformance

In mature testosterone gel markets, originators may outperform peers when they have:

• stronger access in high-coverage formularies,
• better patient support programs,
• packaging preference that reduces switching friction.

However, once category competition is broad, the dominant determinant becomes net pricing and rebate economics rather than clinical differentiation.

What does TESTIM’s financial trajectory imply for future revenue exposure?

Revenue exposure assessment framework

TESTIM’s revenue risk increases when:

• Orange Book coverage thins and remaining patents are narrow,
• multiple AB alternatives are available in key payers,
• wholesale pricing drops propagate into net price compression,
• prescriber switching increases due to formulary normalization.

Conversely, revenue can stabilize when:

• launch is staggered by litigation settlements,
• remaining patents delay additional AB entry,
• branded net contracting retains a meaningful share of covered patients.

Key Takeaways

• TESTIM’s market dynamics are governed by mature category competition where payer formulary design and net price compression drive revenue more than clinical positioning.
• Generic entry risk rises as remaining Orange Book-listed patents age or narrow, shifting the trajectory from “controlled erosion” to faster step-down once multiple AB-rated gels are available.
• Litigation and settlement outcomes can delay specific launches but usually cannot prevent eventual category-wide pricing pressure once the competitive set broadens.
• For financial forecasting, track Orange Book listings tied to composition/formulation and method-of-use coverage, and monitor the number and timing of ANDA approvals that gain AB interchangeability.

FAQs

1. How fast do testosterone gel brands lose sales after AB-rated generic entry?
2. Which Orange Book patent types most often delay ANDA approvals for topical testosterone gels?
3. Do method-of-use patents on testosterone replacement therapies meaningfully block generic substitution?
4. What payer mechanisms (prior authorization, step therapy, rebate tiers) most impact TESTIM utilization?
5. How do gel formulation differences affect FDA bioequivalence and payer acceptance for AB-rated competitors?

References

1. FDA Orange Book. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). U.S. Food and Drug Administration.
2. U.S. FDA. ANDAs and Therapeutic Equivalence (AB Rating) Framework. Food and Drug Administration.